Three of the top five buyouts of 2021 happened in the final quarter, and with biotech stocks hurting many hope that the flurry will continue.
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.